Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment. 

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia. 

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma. 

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma 

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.   

Broadening Differentials in Brain-Metastatic Prostate Cancer Broadens Diagnostic Horizons

Sameer Patel, MD, FACS, of Fox Chase Cancer Center, was recently named Vice President of the Robert H. Ivy Society of Plastic Surgeons. 

Fox Chase Cancer Center’s Dr. Sameer Patel Named Vice President of the Robert H. Ivy Society of Plastic Surgeons

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Assessing Liver Function in Patients with HCC

Videos

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

Risk Factors of Hepatocellular Carcinoma (HCC)

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

Importance of Assessing Liver Function in HCC

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

Assessing Liver Function in Patients With HCC: The ALBI Score

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

Assessing Liver Function in Patients With HCC: The Child-Pugh Score

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

Assessing Liver Function in Patients With HCC: The MELD Score

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Updates in First-Line Systemic Therapy for Patients With HCC

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

Key Outcomes Data in Patients With HCC Based on Liver Function

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

The Future of Liver Function Assessments in HCC

Insights Video Series

Updates in First-Line Systemic Therapy for Patients With HCC

EP: 1.Risk Factors of Hepatocellular Carcinoma (HCC)

EP: 2.Importance of Assessing Liver Function in HCC

EP: 3.Assessing Liver Function in Patients With HCC: The ALBI Score

EP: 4.Assessing Liver Function in Patients With HCC: The Child-Pugh Score

EP: 5.Assessing Liver Function in Patients With HCC: The MELD Score

EP: 6.Updates in First-Line Systemic Therapy for Patients With HCC

EP: 7.Key Outcomes Data in Patients With HCC Based on Liver Function

EP: 8.Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

EP: 9.The Future of Liver Function Assessments in HCC

Latest Conference Coverage